Browse the evidence

Resmetirom (Rezdiffra), a thyroid hormone receptor-beta (THR-β) agonist, is the first FDA-approved pharmacotherapy for non-cirrhotic MASH in adults with moderate to advanced liver fibrosis (F2-F3), demonstrating significant resolution of MASH and improvement in liver fibrosis compared to placebo.

If you have non-cirrhotic MASH with moderate to advanced fibrosis, ask your doctor about Resmetirom (Rezdiffra). It is the first FDA-approved drug for this condition, taken orally alongside diet and exercise, and has been shown to significantly improve liver health compared to placebo.

Subcutaneous semaglutide (0.5-1.0 mg) and oral semaglutide (7-14 mg) significantly improve glycemic control (HbA1c reduction) in patients with type 2 diabetes compared to placebo and various active control drugs.

For individuals with type 2 diabetes, semaglutide (available as a once-weekly injection or daily oral tablet) is highly effective at lowering blood sugar levels (HbA1c) compared to many other treatments, including insulin and other common diabetes medications. It offers a significant advantage in achieving target HbA1c levels (<7%) for a large proportion of patients. The risk of hypoglycemia is relatively low, and the once-weekly dosing can help improve compliance.

Baseline HbA1c levels in Type 2 Diabetes patients have significantly declined over time (from ~10.6% to ~7.9%), reflecting improved glycemic control in clinical trial populations.

Blood sugar control in Type 2 Diabetes has improved significantly over the last 35 years, with average baseline HbA1c dropping from 10.6% to 7.9%. This suggests that modern detection and management strategies are more effective. However, this improvement in glucose control has not prevented the rise in obesity, meaning you must address both metrics.

Obesity is the greatest predictor of type 2 diabetes onset, with obese individuals being five times more likely to develop it than those of healthy weight.

If you are obese, you are five times more likely to develop type 2 diabetes than someone of healthy weight. Weight management is critical for preventing or managing diabetes. Focus on achieving and maintaining a healthy weight through lifestyle changes.

GLP-1 receptor agonists (GLP-1RA) are effective pharmacological interventions for obesity that work by binding to GLP-1 receptors to stimulate insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite.

GLP-1 receptor agonists are a key pharmacological tool for treating obesity. They work by mimicking a gut hormone to reduce appetite and improve metabolic function. Consult a doctor to see if this treatment is appropriate for you.

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) and GLP-1 receptor agonists (e.g., liraglutide) provide robust cardiorenal protection in type 2 diabetes, reducing cardiovascular mortality, heart failure hospitalizations, and kidney disease progression independent of glycemic control.

If you have Type 2 Diabetes and heart or kidney issues, standard sugar-lowering drugs may not be enough. Newer classes of drugs (SGLT2 inhibitors like Jardiance/Farxiga and GLP-1 agonists like Ozempic/Victoza) are proven to significantly reduce the risk of heart attacks, heart failure hospitalizations, and kidney failure. These benefits occur even if your blood sugar numbers don't change drastically, so discuss these specific organ-protective benefits with your doctor.

Females with severe obesity face a disproportionately higher relative risk for stroke, total CVD, and all-cause mortality compared to males with similar obesity levels.

Women with obesity should be particularly vigilant about stroke risk, as their relative risk increases more sharply with obesity severity than men's. Regular cardiovascular screening is essential for women with higher BMI.

Metformin therapy reduces the incidence of new-onset type 2 diabetes in high-risk adults (BMI ≥35, age 25-59, fasting glucose ≥110 mg/dL, or prior gestational diabetes) and provides long-term cardiovascular and microvascular benefits.

If you are at high risk for type 2 diabetes (overweight, older than 25, or have a history of gestational diabetes), metformin can help prevent the disease. It is cost-effective and provides long-term benefits even after stopping the drug. Discuss with your doctor if you are a candidate, especially if lifestyle changes alone are insufficient.

Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major adverse cardiovascular events (MACE), cardiovascular death, and all-cause death in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.

If you have type 2 diabetes and existing heart disease, ask your doctor about GLP-1 receptor agonists like semaglutide. These medications, taken as a weekly injection, have been proven to significantly lower your risk of heart attacks, strokes, and death compared to standard treatments. This is a critical step for protecting your heart and kidneys.

Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major renal events, cardiovascular death, and all-cause death in patients with type 2 diabetes and chronic kidney disease.

If you have type 2 diabetes and chronic kidney disease, ask your doctor about weekly semaglutide injections. This treatment has been shown to significantly slow the progression of kidney disease and reduce the risk of heart-related death and overall death, offering strong protection for your kidneys and heart.

Semaglutide reduces the incidence of major cardiovascular adverse events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) in patients with pre-existing cardiovascular disease and overweight/obesity, regardless of diabetes status.

If you have existing heart disease and are overweight, semaglutide may significantly lower your risk of heart attack, stroke, or cardiovascular death. This benefit exists even if you do not have diabetes.

SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients with cardio-renal-metabolic syndrome, regardless of diabetes status.

If you have heart failure, chronic kidney disease, or type 2 diabetes with high cardiovascular risk, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys, not just your blood sugar, and work even if you don't have diabetes. The benefits are substantial and supported by major clinical trials.

Mechanical tension is the primary and sufficient stimulus for load-induced human skeletal muscle hypertrophy, whereas acute hormonal spikes, metabolic stress, and cell swelling ('the pump') do not meaningfully contribute to the hypertrophic process.

To build muscle, prioritize mechanical tension through resistance training (lifting weights with progressive overload). Do not design your workouts around chasing a 'pump' or relying on metabolic stress (high reps, short rest) as primary drivers, as these do not add to hypertrophy beyond what mechanical tension provides. Similarly, do not expect natural acute hormonal spikes to drive growth; they are not required for hypertrophy to occur.

High-efficacy anti-obesity medications (AOMs) like semaglutide and tirzepatide produce significant weight loss in the majority of patients, but a subset of non-responders exists, and predictors of response or intolerance are currently unknown.

High-efficacy AOMs like semaglutide and tirzepatide work for most people, but not all. If you are a non-responder, it is not your fault, and current science cannot yet predict who will respond. Discuss alternative strategies or phenotypes with your provider.

GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide) reduce major adverse cardiovascular events (MACE) in obese patients without diabetes, independent of weight loss alone.

If you are obese and have existing heart disease, ask your doctor about GLP-1 agonists like semaglutide. They significantly lower your risk of heart attack and stroke, offering protection beyond just weight loss.

GLP-1 and GIP/GLP-1 agonists improve heart failure with preserved ejection fraction (HFpEF) symptoms and functional capacity in obese patients, independent of diabetes status.

If you have obesity and heart failure with preserved ejection fraction, discuss GLP-1 agonists with your cardiologist. They can significantly improve your heart failure symptoms, exercise capacity, and quality of life.

GLP-1 and GIP receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease, independent of weight loss magnitude.

For patients with type 2 diabetes and existing heart disease, GLP-1 therapies like liraglutide and semaglutide significantly reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death). This benefit exists alongside weight loss and may be partly due to direct protective effects on the heart and blood vessels. These drugs are now a standard part of care for high-risk diabetic patients.

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce cardiovascular death, heart failure hospitalizations, and renal composite outcomes in patients with type 2 diabetes and chronic kidney disease, regardless of baseline glycemic control.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like empagliflozin or dapagliflozin. These medications are proven to significantly lower your risk of heart failure, kidney failure, and death, offering protection beyond just blood sugar control.

GLP-1 receptor agonists (liraglutide, semaglutide) reduce major adverse cardiovascular events (MACE) and nephropathy progression in high-risk patients with Type 2 Diabetes.

For those with Type 2 Diabetes and high heart risk, GLP-1 agonists like liraglutide or semaglutide offer strong protection against heart attacks and strokes, as well as kidney damage. Discuss these options with your doctor, especially if you are overweight.

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about SGLT-2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys beyond just lowering blood sugar, significantly reducing the risk of heart failure hospitalization and death. Be aware of potential side effects like infections, but discuss how the heart benefits may outweigh these risks for your specific health profile.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with Type 2 Diabetes and established CVD, primarily through weight loss, blood pressure reduction, and anti-inflammatory effects.

If you have Type 2 Diabetes and heart disease, GLP-1 agonists (like semaglutide or liraglutide) are highly effective at reducing the risk of heart attacks, strokes, and death. They work by mimicking a gut hormone to lower blood sugar, promote weight loss, and reduce blood pressure. While they require injections and may cause temporary stomach issues, the heart protection benefits are substantial and well-documented.

Obesity increases the risk of various cancers (e.g., breast, colorectal, liver) through mechanisms involving chronic inflammation, oxidative stress, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin).

Obesity increases your risk for several types of cancer through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Obesity contributes to cardiovascular disease (CVD) through mechanisms including adipose tissue dysfunction, ectopic fat deposition, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin), leading to hypertension, atherosclerosis, and heart failure.

Obesity increases your risk for heart disease and stroke through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Discontinuation of semaglutide or tirzepatide leads to significant weight regain, indicating that these therapies require long-term use to maintain metabolic benefits.

If you stop taking semaglutide or tirzepatide, you will likely regain most of the weight you lost. These drugs treat obesity and diabetes as chronic conditions, meaning they are meant to be taken long-term to maintain the health benefits. Stopping them reverses the progress made.